Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 3/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630463 | 0.90 | LPAR1 (0.45) | LPAR1LPAR5MAOBSCN9ASCN3A | |
| SCHEMBL3996243 | 0.90 | TP53 (0.48) | LPAR1LPAR5MAOBTSPOPARP15 | |
| SCHEMBL4629897 | 0.90 | LPAR1 (0.53) | LPAR1LPAR5MAOBALOX5SCN9A | |
| Tert-Butylamine SCHEMBL5309305 | 0.86 | LPAR1 (0.49) | LPAR1LPAR5MAOBALOX5SCN9A | |
| SCHEMBL3997271 | 0.86 | PLA2G1B (0.46) | TSPOALDH1A1KDM4EHPGDTRPM8 | |
| SCHEMBL4630557 | 0.82 | HTR2A (0.47) | MAOBALOX5 | |
| SCHEMBL4630536 | 0.80 | LPAR1 (0.51) | LPAR1LPAR5MAOBTSPOHSD17B10 | |
| SCHEMBL5316248 | 0.80 | LPAR1 (0.41) | LPAR1LPAR5MAOBSCN9ASCN3A | |
| Amantadine SCHEMBL5313198 | 0.80 | LPAR1 (0.43) | LPAR1LPAR5MAOBALOX5SCN9A | |
| SCHEMBL3997798 | 0.79 | TRPM8 (0.52) | LPAR1LPAR5MAOBTSPOPARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517883-B8 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-05-21 | — | — | EP | disclosed |
| US-7355069-B2 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| EP-1517883-B1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20050256198-A1 | Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1517883-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | AstraZeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000790-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256198-A1 | Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance | GPR119, INSR, IRS1 | LPAR1 2995/4885LPAR5 3941/4885MAOB 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.